Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Cash from Operations (2016 - 2025)

Karyopharm Therapeutics' Cash from Operations history spans 14 years, with the latest figure at 11828000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 54.17% year-over-year to 11828000.0; the TTM value through Dec 2025 reached 75369000.0, up 40.88%, while the annual FY2025 figure was 75369000.0, 40.88% up from the prior year.
  • Cash from Operations reached 11828000.0 in Q4 2025 per KPTI's latest filing, down from 5860000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 25475000.0 in Q4 2021 to a low of 59197000.0 in Q1 2022.
  • Average Cash from Operations over 5 years is 27612400.0, with a median of 26326500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: surged 183.16% in 2021, then tumbled 205.37% in 2022.
  • A 5-year view of Cash from Operations shows it stood at 25475000.0 in 2021, then crashed by 205.37% to 26843000.0 in 2022, then surged by 30.76% to 18585000.0 in 2023, then plummeted by 38.88% to 25810000.0 in 2024, then surged by 54.17% to 11828000.0 in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Cash from Operations are 11828000.0 (Q4 2025), 5860000.0 (Q3 2025), and 18697000.0 (Q2 2025).